December 2008 Volume 8 Number 12
Visit Nature Reviews Cancer online to browse the journal.
Now available at http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0cZl0Ek
Please note that you need to be a subscriber to enjoy full text access to
Nature Reviews Cancer online. To purchase a subscription,
please visit: http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0a5J0EX
Alternatively, to recommend a subscription to your library, please visit
http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0sRD0EE
*********************************************************************
Nature Reviews Cancer Impact Factor: 29.19 *
(*Journal Citation Reports, Thomson, 2007)
*********************************************************************
=========================== ADVERTISEMENT ===========================
Translational Genomics Solutions with Almac Diagnostics
Almac are experts in biomarker discovery and validation, bioinformatics
solutions and genomic services.
Why Almac?
We have developed our own IVD tests from FF & FFPE as well as our Cancer DSA(TM)
technology. We have expertise in clinical trial design and extensive disease knowledge.
To find out more visit us http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCTi0EC
=========================== ADVERTISEMENT ===========================
IT'S NOW FREE TO POST YOUR VACANCY ON
naturejobs.com http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0bZD0E4
It's the breakthrough you've been waiting for. Naturejobs.com -
the scientific jobs board from Nature -
now lets you advertise your vacancy completely FREE OF CHARGE
Go to http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0BGJp0EC or telephone:
Europe: +44 (0) 20 78434961
US: + 1 800 9897718
=========================== ADVERTISEMENT ===========================
Announcing an open access option in British
Journal of Cancer.
An open access option is now available to
all authors of original research papers
that are accepted for publication in BJC.
BJC OPEN articles will be freely accessible
to all readers immediately on publication.
Learn more about BJC OPEN by visiting BJC online at
http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCTj0ED
=====================================================================
From the editors
p901 | doi:10.1038/nrc2558
http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCTk0EE
----------------------
RESEARCH HIGHLIGHTS
----------------------
Tumorigenesis: Domain game
p903 | doi:10.1038/nrc2548
http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCTl0EF
Aneuploidy: Hyperactivity disorder
p904 | doi:10.1038/nrc2549
http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCTm0EG
Genomic instability: Another string to the bow
p904 | doi:10.1038/nrc2555
http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCTn0EH
Glioblastoma: Stop acting so immature
p905 | doi:10.1038/nrc2546
http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCTo0EI
Signalling: Making more of a mark
p906 | doi:10.1038/nrc2551
http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCTp0EJ
Immunotherapy: It pays to be persistent
p906 | doi:10.1038/nrc2554
http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCTq0EK
IN THE NEWS
Engineering a better diet
p906 | doi:10.1038/nrc2557
http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCTr0EL
IN BRIEF
Apoptosis | Tumour biology | Gene profiling
p907 | doi:10.1038/nrc2553
http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCTs0EM
Stem cells: A new pathway for stem cell ageing and renewal
p908 | doi:10.1038/nrc2547
http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCTt0EN
Tumour supression: Lost in translation
p908 | doi:10.1038/nrc2550
http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCTu0EO
Tumour microenvironment: There goes the neighbourhood
p908 | doi:10.1038/nrc2556
http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCTv0EP
TRIAL WATCH
KRAS mutations and cetuximab
p909 | doi:10.1038/nrc2552
http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCTw0EQ
----------------------
PROGRESS
----------------------
Non-coding RNA production by RNA polymerase III is implicated in cancer
Lynne Marshall and Robert J. White
p911 | doi:10.1038/nrc2539
Increased RNA polymerase III activity in cancer has been observed for over
30 years but how this occurs and affects cellular transformation is only
beginning to be understood. Lynne Marshall and Robert J. White discuss recent
progress made in this emerging field.
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCTx0ER
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCTy0ES
=========================== ADVERTISEMENT ===========================
Get clinically relevant information from FFPE tissues with Asuragen's
ENCOMPASS Services for FFPE. Asuragen offers the best technologies for
FFPE from ABI, Affymetrix, Agilent, Illumina, and NuGEN. All work is done
in our GLP/CLIA-registered facility under the guidance of on-staff pathologists
and experts trained to help you get most from this information rich source.
http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CBY10EK
=====================================================================
----------------------
REVIEWS
----------------------
Insulin and insulin-like growth factor signalling in neoplasia
Michael Pollak
p915 | doi:10.1038/nrc2536
Insulin and insulin-like growth factors (IGFs) are well-known as key
regulators of energy metabolism and growth and have important roles in
neoplasia. This Review documents the various methods are being used to
investigate novel cancer prevention and treatment strategies related to
insulin and IGF signalling.
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCTz0ET
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCT10EG
The ADAMs: signalling scissors in the tumour microenvironment
Gillian Murphy
p932 | doi:10.1038/nrc2459
The disintegrin metalloproteinases of the Adam (a disintegrin and metalloproteinase)
family mediate proteolytic 'shedding' of membrane-associated proteins and hence
rapidly modulate key cell signalling pathways in the tumour microenvironment.
What is the biological and clinical relevance of the ADAMs?
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCT20EH
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCT30EI
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
Christian Fischer, Massimiliano Mazzone, Bart Jonckx and Peter Carmeliet
p942 | doi:10.1038/nrc2524
Anti-angiogenic drugs have become part of the standard therapeutics used to
treat cancer. Despite this milestone, anti-angiogenic therapy still faces a
number of clinical hurdles. Will other agents with complementary mechanisms
offer novel opportunities for improved treatment?
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCT40EJ
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCT50EK
=========================== ADVERTISEMENT ===========================
Save 15% on DNA Labeling for CGH
Take advantage of Agilent's new Genomic DNA Enzymatic Labeling Kit and
get 15% off your purchase. You'll get superior data quality on your
microarray-based CGH experiments, and you'll have the advantage of buying
from an ISO 13485 compliant manufacturer. Act now and save!
http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCT60EL
=====================================================================
----------------------
PERSPECTIVES
----------------------
OPINION
[gamma]H2AX and cancer
William M. Bonner, Christophe E. Redon, Jennifer S. Dickey, Asako J. Nakamura,
Olga A. Sedelnikova, Stephanie Solier and Yves Pommier
p957 | doi:10.1038/nrc2523
DNA double strand breaks (DSBs) may lead to cancer but, paradoxically,
are also used to kill cancer cells. How might [gamma]H2AX - a
surrogate marker of DSBs - be used to detect precancerous cells,
to stage cancers, to monitor the effectiveness of cancer therapies and to
develop novel anticancer drugs?
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCT70EM
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCT80EN
TIMELINE
The impact of O2 availability on human cancer
Jessica A. Bertout, Shetal A. Patel and M. Celeste Simon
p967 | doi:10.1038/nrc2540
During the past century, the response to hypoxia has emerged as an important
phenotypic determinant of a tumour, with repercussions for sensitivity to
radiation and chemotherapy. This Timeline provides a historical overview of
responses to hypoxia while looking forward to therapeutic strategies that
are being developed to exploit them.
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCUA0EX
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCUB0EY
TIMELINE
Reflecting on 25 years with MYC
Natalie Meyer and Linda Z. Penn
p976 | doi:10.1038/nrc2231
MYC is an iconic oncogene that has been at the forefront of cancer research
since its discovery. Looking back over the history of MYC research provides
us with a framework with which to progress in the next 25 years, as outlined
in this Timeline.
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCUC0EZ
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCUD0Ea
----------------------
CORRESPONDENCE
----------------------
Correspondence: On clonogenic tumour cells and metastasis-forming cells
Maurice Tubiana and Serge Koscielny
p990 | doi:10.1038/nrc2419-c1
http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCUE0Eb
Correspondence: Clonogens and cancer stem cells
Michael Baumann, Mechthild Krause and Richard Hill
p990 | doi:10.1038/nrc2419-c2
http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0CCUF0Ec
=========================== ADVERTISEMENT ===========================
SUBSCRIBE to Nature Reviews Cancer TODAY and receive your own personal
copy delivereddirectly to your door each month. PLUS you will gain full
online access to the entire archive since launch.
http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0a5J0EX
Nature Reviews Cancer is the no. 1 monthly review journal in oncology*.
Ensure you have access.
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to
receive it. You can change or discontinue your e-mail alerts at any time,
by modifying your preferences on your nature.com account at:
http://ealerts.nature.com/cgi-bin24/DM/y/eo260Xztnp0Hja0Zzu0EI
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2008 Nature Publishing Group
=====================================================================
